



HAL
open science

From experimental setup to bioinformatics: an RNAi screening platform to identify host factors involved in HIV-1 replication

Kathleen Börner, Johannes Hermle, Christoph Sommer, Nigel P Brown, Bettina Knapp, Glass Bärbel, Julian Kunkel, Gloria Torralba, Jürgen Reymann, Nina Beil, et al.

► To cite this version:

Kathleen Börner, Johannes Hermle, Christoph Sommer, Nigel P Brown, Bettina Knapp, et al.. From experimental setup to bioinformatics: an RNAi screening platform to identify host factors involved in HIV-1 replication. *Biotechnology Journal*, 2009, 5 (1), pp.39. 10.1002/biot.200900226 . hal-00545273

HAL Id: hal-00545273

<https://hal.science/hal-00545273>

Submitted on 10 Dec 2010

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



**From experimental setup to bioinformatics: an RNAi
screening platform to identify host factors involved in HIV-1
replication**

Journal:	<i>Biotechnology Journal</i>
Manuscript ID:	biot.200900226.R1
Wiley - Manuscript type:	Technical Report
Date Submitted by the Author:	11-Oct-2009
Complete List of Authors:	<p>Börner, Kathleen; Hygiene Institute, University of Heidelberg Medical School, Department of Virology, Hermle, Johannes; Hygiene Institute, University of Heidelberg Medical School, Department of Virology, Sommer, Christoph; Heidelberg Collaboratory for Image Processing (HCI), University of Heidelberg, Brown, Nigel; Structural and Computational Biology Unit, European Molecular Biology Laboratory, Knapp, Bettina; Viroquant Research Group Modeling, Bioquant Center, University of Heidelberg, Bärbel, Glass; Hygiene Institute, University of Heidelberg Medical School, Department of Virology, Kunkel, Julian; Parallel and Distributed Systems, Institute for Informatics, University of Heidelberg, Torralba, Gloria; Kirchhoff Institute of Physics, University of Heidelberg, Reymann, Jürgen; Viroquant-CellNetworks RNAi Screening Facility, Bioquant Center, University of Heidelberg, Beil, Nina; Viroquant-CellNetworks RNAi Screening Facility, Bioquant Center, University of Heidelberg, Beneke, Jürgen; Viroquant-CellNetworks RNAi Screening Facility, Bioquant Center, University of Heidelberg, Pepperkok, Rainer; Cell Biology and Cell Biophysics Unit, European Molecular Biology Laboratory, Schneider, Reinhard; Structural and Computational Biology Unit, European Molecular Biology Laboratory, Ludwig, Thomas; Parallel and Distributed Systems, Institute for Informatics, University of Heidelberg, Hausmann, Michael; Kirchhoff Institute of Physics, University of Heidelberg, Hamprecht, Fred; Heidelberg Collaboratory for Image Processing (HCI), University of Heidelberg, Erfle, Holger; Viroquant-CellNetworks RNAi Screening Facility,</p>

	Bioquant Center, University of Heidelberg, Kaderali, Lars; Viroquant Research Group Modeling, Bioquant Center, University of Heidelberg, Kräusslich, Hans-Georg; Hygiene Institute, University of Heidelberg Medical School, Department of Virology, Lehmann, Maik; Hygiene Institute, University of Heidelberg Medical School, Department of Virology,
Keywords:	siRNA, RNA interference, high-throughput screening, HIV



For Peer Review

Technical Report ((7261 words))**From experimental setup to bioinformatics:
an RNAi screening platform to identify host factors involved
in HIV-1 replication**

Kathleen Börner^{1#}, Johannes Hermle^{1#}, Christoph Sommer², Nigel P. Brown³, Bettina Knapp⁴,
Bärbel Glass¹, Julian Kunkel⁵, Gloria Torralba⁶, Jürgen Reymann⁷, Nina Beil⁷, Jürgen
Beneke⁷, Rainer Pepperkok⁸, Reinhard Schneider³, Thomas Ludwig⁵, Michael Hausmann⁶,
Fred Hamprecht², Holger Erfle⁷, Lars Kaderali⁴, Hans-Georg Kräusslich¹, Maik J. Lehmann^{1*}

(1) Department of Virology, Hygiene Institute, University of Heidelberg Medical School, Heidelberg, Germany. (2) Heidelberg Collaboratory for Image Processing (HCI), University of Heidelberg, Heidelberg, Germany. (3) Structural and Computational Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany. (4) Viroquant Research Group Modeling, Bioquant Center, University of Heidelberg, Heidelberg, Germany. (5) Parallel and Distributed Systems, Institute for Informatics, University of Heidelberg, Heidelberg, Germany. (6) Kirchhoff Institute of Physics, University of Heidelberg, Heidelberg, Germany. (7) Viroquant-CellNetworks RNAi Screening Facility, Bioquant Center, University of Heidelberg, Heidelberg, Germany. (8) Cell Biology and Cell Biophysics Unit, European Molecular Biology Laboratory, Heidelberg, Germany.

* To whom correspondence should be addressed

The first two authors contributed equally to this work

1
2 Correspondence: Maik J. Lehmann, Department of Virology, Hygiene Institute, University of
3
4 Heidelberg Medical School, Im Neuenheimer Feld 324, 69120 Heidelberg, Germany.

5
6
7 Email: maik.lehmann@med.uni-heidelberg.de

8
9 Fax: +496221 – 565003

10
11
12
13 Keywords: siRNA, RNA interference, high-throughput screening, HIV

14
15 Abbreviations: GFP, green fluorescent protein; HIV, Human Immunodeficiency Virus; RNAi,
16
17 RNA interference; siRNA, small interfering RNA

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Abstract

RNA interference (RNAi) has emerged as a powerful technique for studying loss of function phenotypes by specific down-regulation of gene expression, allowing the investigation of virus-host interactions by large-scale high-throughput RNAi screens. Here we present a robust and sensitive siRNA screening platform consisting of an experimental setup, single-cell image and statistical analysis as well as bioinformatics. The workflow has been established to elucidate host gene functions exploited by viruses, monitoring both suppression and enhancement of viral replication simultaneously by fluorescence microscopy. The platform comprises a two-stage procedure in which potential host factors are first identified in a primary screen and afterwards re-tested in a validation screen to confirm true positive hits. Subsequent bioinformatics allows the identification of cellular genes participating in metabolic pathways and cellular networks utilised by viruses for efficient infection. Our workflow has been used to investigate host factor usage by the human immunodeficiency virus-1 (HIV-1), but can also be adapted to other viruses. Importantly, we expect the description of the platform will guide further screening approaches for virus host interactions. Moreover, the ViroQuant-CellNetworks RNAi Screening core facility is an integral part of the recently founded BioQuant centre for systems biology at the University of Heidelberg providing service to external users in the next future.

Deleted: -

Deleted: f

Deleted: -

Deleted: -

1 Introduction

Despite considerable advances in virological research over the last few decades, viruses continue to represent a major health risk responsible for millions of deaths worldwide each year. Like other viruses, HIV-1 has evolved the capability to successfully infect - and efficiently transmit between - human cells by recruiting various host proteins for each step of its life cycle [1-3]. Unravelling these critical cellular factors will not only improve our fundamental understanding of HIV-host interactions, but may eventually lead to novel anti-HIV therapeutics. Since the rate of mutations of cellular genes is substantially lower than for viral genomes, the particular benefit of targeting host factors is that it may provide a higher barrier to the generation of anti-drug resistance. A most powerful and versatile approach to identify such potential cellular interaction partners of HIV-1 are RNAi-based loss-of-function screens, as suggested by very recent reports [4-6].

Deleted: -

Deleted: -

Deleted: -

Deleted: -

Although each of the three high-throughput screens published thus far reported a large number of potential host cell factors, there is only little overlap between the different sets [7-9]. This might be explained by differences in the individual experimental conditions, such as the use of distinct cell lines, siRNA libraries or virus strains, all of which could have significantly affected the results. Importantly, however, it may also be due to the use of different criteria for defining a "hit" or inconsistencies concerning the techniques applied to validate potential hits [9]. This highlights the need for comparable experimental conditions in further studies and for the selection of consistent analytical methods for future screening approaches.

In this report we describe a sensitive, automated microscopy-based siRNA screening platform, which has been designed to elucidate host factors utilised by a variety of viruses.

Deleted: -

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

This platform has been used for studying host cell interactions of infectious HIV-1. The detailed description of the experimental setup as well as guidance on subsequent image analysis, statistical methods and bioinformatics approaches provides essential information for establishing further screening platforms.

In our platform several sub-genomic siRNA libraries are tested in a primary screen and the identified potential hits are subsequently re-confirmed in a validation screen using different siRNAs. In both screening stages a non-silencing siRNA and an siRNA targeting the HIV-1 specific cell surface receptor CD4 are used as negative and positive control, respectively. In addition, the knockdown efficacy and cytotoxicity of siRNAs are determined within the validation screen. Genes showing similar effects in both the primary and the validation screen are considered as validated. Bioinformatics and modelling approaches on the validated hits in combination with published HIV-1 host factors, known metabolic pathways and protein-protein interactions enable the identification of cellular networks and pathways involved in the replication of HIV-1. Further studies using this platform will characterise fundamental cellular functions of the identified hits and will shed light on their role in viral pathogenesis.

2 Experimental Setup

The key elements of the experimental setup are the reverse transfection of commercially available siRNA libraries into HIV-permissive HeLa P4 cells (Fig. 1A). Following a 36 hour incubation period to allow target knockdown, the cells are infected with HIV-1 virions encoding for GFP (Fig. 1B). This allows the straight-forward detection and quantitation of infected cells via a highly sensitive automated microscopy-based assay (Fig. 1C).

2.1 Preparation of the siRNA arrays

The platform was initially established for chambered coverglasses (LabTeks, NUNC, Thermo

1
2 Fisher Scientific, Langensfeld, Germany), allowing the investigation of up to 384 individual
3 spotted siRNAs per LabTek. LabTekes are characterised by easy cell and liquid handling. As
4 only a few cells can be monitored per spot, we considered at least eight replicates necessary
5 for a statistically reliable analysis. Later experiments showed that 384-well plates (BD
6 FALCON 353962, BD Biosciences, Heidelberg, Germany) were more suitable for our high-
7 throughput screening approach, as more images per well could be collected compared to
8 LabTekes resulting in a higher number of cells for statistical analysis. Therefore 384-well
9 plates have the advantage of providing stronger statistical power even with only two or three
10 replicates, which is supported by the high correlation as shown in Fig. 2A. However, more
11 sophisticated automated liquid handling devices are needed (for more information, see
12 "Infection Assay").
13
14
15
16
17
18
19
20
21
22

23 For validation screens, 96-well plates (Corning COSTAR 3603, Corning Life Sciences,
24 Amsterdam, The Netherlands) are used, allowing collection of even more images per well
25 compared to 384-wells. All experiments were performed with HeLa P4 cells as they are well
26 suited for culturing in all of the tested well plates and also highly transfectable with siRNAs
27 (data not shown).
28
29
30
31
32
33

34 In order to keep replicates as reproducible as possible, the siRNA libraries are printed in a
35 batchwise manner using a previously described reverse transfection protocol [10, 11]. To this
36 end, a mixture of the respective siRNA, the transfection reagent Lipofectamine 2000
37 (Invitrogen GmbH, Karlsruhe, Germany), fibronectin (Sigma-Aldrich Chemie GmbH,
38 Taufkirchen, Germany), sucrose (USB Corporation, Ohio, USA) and gelatine (Sigma-Aldrich,
39 Steinheim, Germany) are transferred automatically to a 384-well plate or any other cell
40 culture format. After drying of the mixture in the well, the substrates can either be stored for
41 up to 15 months without any loss of efficacy or can be directly used for knockdown studies
42 [10]. This is a major advantage of the reverse transfection method compared to liquid
43 transfection, as it permits better reproducibility and comparability between different plates of
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 the same batch.
3
4

5 For the primary screen, various libraries containing *silencer* siRNAs (Ambion, Applied
6 Biosystems, Austin, TX, USA) are used in 384-well plates or LabTeks, with one individual
7 siRNA per well/spot and three distinct siRNAs per target gene. Contrary to individual siRNAs,
8 “pooled siRNAs” are considered to achieve a more potent knockdown by the synergistic
9 effects of combining several siRNAs targeting the same gene. However, less active siRNAs
10 may interfere with the efficacy of highly active siRNAs and attenuate their effect.
11
12
13
14
15
16

17
18 Potential host factors identified in the primary screen as “hits” (for more information, see
19 “Statistical Analysis”) are subsequently re-tested within a validation screen with a minimum of
20 five replicates in 96-well plates. Per gene, at least two novel chemically modified siRNAs
21 (*silencer select* siRNAs, Ambion, Applied Biosystems, Austin, TX, USA) are used to enhance
22 specificity and minimise “off-target effects”. Two siRNAs against CD4 were chosen as
23 positive controls: for the primary screen: 5'-GAUCAAGAGACUCCUCAGUTT-3' [12] and for
24 the validation screen: Ambion *silencer select* “s2579”. The non-silencing controls are:
25 Primary screen: 5'-AGGUAGUGUAAUCGCCUUGTT-3' and for the validation screen: Ambion
26 *silencer select* “negative control #1”.
27
28
29
30
31
32
33
34

35
36 To determine a suitable time for efficient siRNA-mediated gene knockdown, the surface
37 expression levels of the HIV-1 specific receptor CD4 were determined by FACS analysis after
38 varying siRNA treatment times. CD4 mediates cell entry of HIV-1 and thus represents a
39 pivotal host factor for HIV-1 infection. Our study revealed a gene knockdown efficiency of
40 approximately 90 % within a period of 24 h up to 92 h after siRNA transfection (data not
41 shown). Thus, in subsequent experiments cells are infected 36 h after transfection and fixed
42 after additional 36 h.
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2.2 Virus constructs, culture and harvesting

In our screens, fully infectious HIV-1 particles encoding the green fluorescence protein (GFP) were used. The construct is derived from wildtype HIV-1 (pNL4-3), in which the *gfp* open reading frame is C-terminally fused to the first 16 amino acids of the *nef* gene (referred to as HIV-1-AGFP, Fig. 1B, [13])

The GFP expression after infection allows a direct measurement of viral replication by fluorescence microscopy, thereby avoiding further time- and cost-intensive working steps like antibody staining or substrate-based indicator assays. Standard protocols for the production of HIV-1-AGFP yielded fully functional particles as described previously [13]. However, we found that particles lost the ability to induce cellular GFP expression, over a period of several weeks, most likely due to high recombination rates. Thus, a commonly used procedure for large-scale virus production was not applicable and the protocol had to be adapted. The most important factor was to limit cell culture to 10 passages. Cell culture and infection conditions were optimised to generate high titres of HIV-1-AGFP as follows. Human embryonic kidney 293T cells are transfected with HIV-1-AGFP proviral DNA. Forty-two hours after transfection, the virus containing supernatant is harvested and used for an initial infection of human C8166 cells. After one passage the virus is used to start a co-culture with MT4 cells for five passages in total. The virus-containing cell culture supernatant is enriched up to 100-fold using the crossflow filtration system VivaFlow 200 (Vivascience AG, Hannover, Germany) and a subsequent ultracentrifugation step.

A typical production round yields 20 mL of virus preparation with an average concentration of 66 µg/mL viral capsid protein (p24), determined by in-house ELISA. Infectivity and functional integrity of produced HIV-1-AGFP particles are confirmed prior to high-throughput screening. Infectivity of the viral particles is verified by measurement of luciferase activity in TZM cells (data not shown). As the assay depends on a GFP reporter, it is crucial that GFP and viral protein expression are correlated. Accordingly, HeLa P4 cells are infected and stained for

1
2 p24 with fluorescently tagged antibodies and subsequently monitored for co-localisation with
3
4 GFP by fluorescence microscopy (Fig. 1C).
5
6
7

8 **2.3 Infection assay**

10 For siRNA transfection and subsequent infection HeLa P4 cells are seeded into siRNA-pre-
11 coated 384-well plates (850 cells/well in 30 μ L) or 96-well plates (2500 cells/well in 100 μ L)
12 using the reagent dispenser MultiDrop[®] Combi (Thermo Fisher Scientific, Langenselbold,
13 Germany) or manually into LabTeks (1.2 x 10⁵ cells/LabTek in 3 mL). Following a 36 hour
14 incubation period for target gene knockdown, the cells are infected with HIV-1-AGFP in a
15 BSL-3 facility, using the compact automated liquid handler Hydra DT (Matrix, Thermo Fisher
16 Scientific, Langenselbold, Germany) for well plates. As we are interested in detecting
17 potential decreases as well as increases in GFP expression in order to identify down- and
18 up-regulating genes in HIV-1 replication, we adjust the infection rate to approximately 30 %
19 (384-well plate: 28 ng p24/well in 30 μ L; 96-well plate: 80 ng p24/well in 50 μ L; LabTek: 6.7
20 μ g p24/LabTek in 2 mL). After an additional 36 h, cells are fixed for 90 min with 4 %
21 paraformaldehyde, removed from the BSL-3 facility and stained for 45 minutes with the dye
22 Hoechst 33258 (330 ng/mL) for cell nuclei detection as further described in "Image Analysis"
23 section.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 **2.4 Image acquisition**

41 For high-throughput image acquisition a fully automated epifluorescence Scan[^]R screening
42 microscope equipped with the Scan[^]R acquisition software (Olympus Biosystems GmbH,
43 M \ddot{u} nster, Germany) is used. Images are acquired with a 10x objective in nine positions per
44 well for 384-well plates, up to 16 positions for 96-well plates and in one position per spot on a
45 LabTek. In each position images are acquired in the Hoechst and in the GFP channel using
46 the corresponding excitation and emission filters.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

2.5 Cytotoxicity and non-specific effects

Cytotoxic siRNAs in the primary screen are filtered out, as described later in “Statistical Analysis”. All validation screen siRNAs are tested for potential confounding effects by the following methods. Cytotoxicity is assessed by the Toxilight Assay Kit (Lonza, Sales Ltd., Basel, Switzerland). General influence of the siRNAs on cellular protein expression is determined using a stably GFP expressing HeLa P4 cell-line seeded onto siRNA-coated cell culture plates under screening conditions, but without viral infection. As variations in GFP intensities reveal a virus-independent siRNA-induced effect on the cellular expression machinery, siRNAs with significant effects on GFP expression are excluded from further investigations. Finally, the knockdown efficacy of the siRNAs used in the validation screen is tested by qRT-PCR (SYBR Green, Applied Biosystems, Darmstadt, Germany).

2.6 Concluding remarks

The specific viral construct (HIV-1-AGFP) was harvested and produced in sufficient amounts for high-throughput screening. Co-localisation of p24 and GFP demonstrated that virus-induced GFP expression is a suitable readout for infection. The siRNA against CD4 and a non-silencing siRNA were established as working positive and negative controls and can be clearly distinguished (Fig. 2B). The platform has been shown to work on all tested cell culture formats. In summary, the screening assay is able to reveal both down- and up-regulating host genes that are modulating HIV-1 replication by altering the GFP-intensity and infection ratio (Fig. 2C).

3 Image Analysis

Image analysis consists of the following three successive steps: (i) Cell nuclei segmentation in the Hoechst channel, (ii) cell segmentation in the GFP channel, and (iii) quantification of cell characteristics. The inputs of the image analysis routine are the Hoechst and GFP channels, representing cell nuclei and cell cytoplasm (Fig. 3A). As output we compute the

1
2 number of nuclei, the average signal intensity over all cells (in the GFP channel), and the
3 proportion of cells which are infected. These calculations are performed per position in a well
4 and serve as input to the statistical analysis.
5
6
7

8 **3.1 Cell nuclei segmentation**

9
10 To segment cell nuclei we use the *marker-controlled watershed transform method* [14]. This
11 method consists of two basic steps. First, the algorithm detects a unique initial *foreground*
12 *marker* for each cell nucleus (typically the marker that corresponds to the center of the
13 object). At the same time *background markers* are extracted, which lie in the dark region
14 between cell nuclei (Fig. 3B). Second, the watershed transform expands markers spatially to
15 enclose the cell nuclei in the image. Finally, basins originating from foreground markers
16 correspond to masks of cell nuclei.
17
18
19
20
21
22
23

24 **3.2 Cell nuclei marker extraction**

25
26 A preliminary binarisation of the Hoechst image is found using a histogram adaptive
27 threshold [15], leading to an initial nuclei versus background mask. In the case of uneven
28 illumination of the image, background correction can be applied before binarisation [16]. A
29 Gaussian blurred version of the cell nuclei image is used to detect foreground markers (the
30 variance for the Gaussian kernel is empirically adapted to cell nuclei size). All local maxima
31 above the binarisation threshold are determined and dilated to suppress spurious markers
32 (Fig. 3B). To extract background markers we compute the Euclidian distance map from the
33 initial binary mask. This map contains the distance from each non-nucleic pixel to its nearest
34 nucleic pixel in the binarised image. All ridges from the distance map are extracted to get a
35 Voronoi-net like background marker (Fig. 3B). Both types of markers (background from
36 distance map, foreground from Gaussian blur) serve as the final markers for the watershed
37 transform operating on the gradient image.
38
39
40
41
42
43
44
45
46
47
48

49 **3.3 Cell segmentation**

50
51 The extracted cell nuclei masks are passed as foreground markers to the cell segmentation
52
53
54
55
56
57
58
59
60

1
2 process. As background markers we re-use the background markers from the cell nuclei
3 segmentation (Fig. 3C). Note that we cannot compute background markers directly from the
4 GFP-channel, as only infected cells are visible in this channel.
5
6
7

8 **3.4 Quantification**

9
10 The main readouts of the image analysis are the **average signal intensity** over all cells in the
11 image, the **number of nuclei**, and the infection ratio. Uninfected cells appear dark, while
12 infected cells show rather high grey values over their area. A Gaussian mixture model with
13 two components is fitted to the extracted mean grey values (Fig. 3D). One Gaussian
14 component explains the variation of uninfected, while the other accounts for the variation of
15 infected cells. If zero or all cells are infected, one of the two components should vanish,
16 however, in practice, an intermediate number of infected cells produces two overlapping
17 components. To remedy this, a prior is imposed on the position of the two Gaussian means,
18 which essentially acts as a repelling force between the mixture components. Having found
19 the parameters of the mixture model, an optimal threshold is computed to classify each cell
20 as infected or not infected. Finally, the infection ratio is computed as the number of infected
21 cells divided by the total cell count.
22
23
24
25
26
27
28
29
30
31
32
33
34

35 **3.5 Implementation and pipeline**

36
37 A fully automated pipeline was set up to process the large number of images produced by
38 the screens. Image processing was implemented in Matlab® and C++ and runs in a data-
39 parallel fashion distributed over a 12x8-core Linux (64bit) compute cluster. For each well
40 position, output is written to a virtual file system which automatically maps data into a
41 relational database for convenient post-processing.
42
43
44
45
46
47

48 **3.6 Concluding remarks**

49
50 The use of parallel batch processing yields a major speed-up as a typical screen with 1.3
51 million images requiring 3.6 TB of storage is processed in approximately 36 h. Automated
52
53
54
55
56
57
58
59
60

1
2 image quality control is being added to exclude foreign bodies and artefacts in images before
3
4 quantification, resulting in improved measurements. A long-term goal is to create a
5
6 framework for interactive statistical learning of segmentation tasks, allowing simple
7
8 adaptation to novel cell types, sensor settings, chemical dyes and assay-specific
9
10 phenotypes, without re-programming the image processing routines.
11

12 13 14 **4 Statistical Analysis**

15
16 Segmented images are processed further statistically, to identify up- and down-regulators of
17
18 viral replication. Based on the number of nuclei per well and the average signal intensity over
19
20 all cells in the GFP channel, our statistical analysis pipeline consists of the following steps: (i)
21
22 Log-transformation of raw data, (ii) normalisation between different plates, (iii) identification
23
24 and removal of siRNAs with cytotoxic effects, (iv) removal of systematic effects of cell counts
25
26 on signal intensity, (v) spatial normalisation within one plate, and (vi) hit calling. The entire
27
28 workflow is complemented by strict quality control, monitoring at each step the quality of raw
29
30 and transformed data. In case of failed quality control for individual wells or plates, these are
31
32 either removed from further analysis or repeated.

33 **4.1 Data normalisation**

34
35 As a first step for the analysis of the data, a log-transformation of the raw data is carried out.
36
37 Since the distribution of raw fluorescence intensities is heavily right-skewed, a logarithmic
38
39 transformation of the data results in a more normal distribution.
40

41
42 In the primary screen, different plates are made comparable by subtracting the plate median
43
44 from each intensity value, and dividing by the median absolute deviation (z-score). These
45
46 two measures are more robust alternatives to the mean and the standard deviation. The
47
48 normalisation steps are based on the assumptions that the siRNAs are randomly distributed
49
50 over the plates, and that most siRNAs will not have an effect on viral replication. Clearly, for
51
52 validation screens, this assumption is not valid. In this case, plates are made comparable by
53
54
55
56
57
58
59
60

1
2 subtracting the median of the negative controls, and dividing by their median absolute
3 deviation.
4

5
6
7 Since some knockdowns will be cytotoxic and therefore will interfere with the readout of viral
8 replication, we exclude wells with the lowest 5% of cell counts in the entire screen.
9 Furthermore, due to possible incorrect segmentation of images with very dense cell
10 populations, wells with the highest 5% of cell counts are also removed. Locally weighted
11 scatterplot smoothing [17] is used to de-correlate signal intensities and cell count, by
12 adjusting the signal intensities for the effect of unequal cell numbers in wells. This is done for
13 each plate individually, since effects may be different from plate to plate. Spatial effects within
14 each plate are then corrected using B-score normalisation [18]. This method adjusts
15 intensities using a median polish procedure on rows and columns separately, thus estimating
16 row- and column-effects on each plate. These estimates are then used to correct each spot
17 individually. The procedure is very effective at removing spatial artefacts such as edge effects
18 on a plate, but rests on the assumptions that siRNAs are randomly placed on the plates, and
19 that most siRNAs do not have an effect on viral replication. This method must therefore not
20 be used in the analysis of secondary / validation screens.
21
22
23
24
25
26
27
28
29
30
31
32

33 **4.2 Statistical testing**

34
35 The current standard practice to select hit genes from RNAi data is to select siRNA hits
36 whose z-score-normalised intensity deviates from the bulk [19], but hits with smaller
37 intensities will be missed using this method [20]. Thus, if enough replicates are available, we
38 use a statistical approach which assigns a p-value to each siRNA. If the p-value is smaller
39 than a given significance level α , the null hypothesis H_0 that assumes no significant effect
40 can be rejected. Since data in this study is more or less normally distributed, we use the one-
41 sample two-sided Welch's t-test to compute p-values. **If siRNAs are randomly distributed on**
42 **a plate and if it can be assumed that most siRNAs have no effect, replicates in the test are**
43 **compared with the overall population, acting as a de-facto negative control. If this assumption**
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 is not valid - e.g. in a validation screen – the test is carried out against negative controls. For
3
4 primary screens, where only two replicates are available and a statistical test is thus not
5
6 feasible, hits are called if their mean z-score over replicates is > 2 (or < -2). For validation
7
8 screens, we combine the information given by z-score and p-value by requiring a p-value $<$
9
10 0.05 and a z-score > 1.5 (or < -1.5), respectively. The p-value ensures that effects are
11
12 repeatable over the replicates, while the z-score assures that they are sufficiently strong on
13
14 average.

15 4.3 Implementation

16
17 The statistical analysis described here was implemented in the free statistical environment R
18
19 (www.R-project.org), and uses the cellHTS [19] and RNAiR [21] Bioconductor packages
20
21 (www.bioconductor.org). The pipeline was integrated into the full screening workflow, and
22
23 generates user-readable HTML webpages for the assessment of data quality and
24
25 normalisation results. Z-scores and p-values are also written to text files for further
26
27 processing (see “Bioinformatics”).
28
29

30 4.4 Concluding remarks

31
32 Statistical analysis is important to robustly identify “hit” genes and avoid errors. Data
33
34 normalisation should be based on controls. This procedure is only valid, if sufficient numbers
35
36 of positive and negative controls have been spotted per plate. This can normally only be
37
38 achieved in validation screens with a custom designed layout. Normalisation on plate
39
40 medians is more robust, but requires random spotting of siRNAs on plates and is feasible
41
42 only for primary screens. Considerable spatial effects are observed in cell arrays, but to a
43
44 lower extent also on well plates, and must be corrected during the normalisation. As the
45
46 correlation between cell numbers and signal intensity is often non-linear, sophisticated
47
48 methods such as lowess normalisation have to be used. With all these considerations the
49
50 raw data produced by the image analysis is analysed and the outcome is represented by
51
52 z-scores.
53
54
55
56
57
58
59
60

5 Bioinformatics

High-throughput screening of many hundreds or thousands of genes requires integration of correspondingly large amounts of data, both from the screens themselves and from external data sources. External data may comprise information about the genes and gene products including cross-references to other data sources, as well as relationships between the genes, such as participation in metabolic pathways, protein-protein interaction and gene regulatory networks.

The principal aims of bioinformatics are (i) to integrate data about biological entities of interest into descriptive or qualitative models, and (ii) to use this as a basis for comparisons and predictions to guide further experimentation.

5.1 Data integration

The suppliers for our siRNA libraries designate target genes using NCBI Entrez GeneID [22] and RefSeq [23] identifiers. Thus the range of possible genes and their associated identifiers in our human screens is NCBI-centric, rather than being based on the overlapping EMBL-EBI/Sanger Ensembl [24] collection. Entrez and RefSeq are continually being updated by NCBI as gene and protein product entries are refined, old records are withdrawn and new records are added, so that the identifiers and data for the gene targets referenced in the libraries, and in published studies, are subject to change. Symbolic gene names are particularly unreliable, so that, when reporting the results of a study, the Entrez and/or RefSeq identifiers as well as the database release from which they were obtained should be reported. The bioinformatics processing stage must track changes in gene accession numbers/identifiers and maintain cross-references to other external data sources, also having potentially changing identifiers.

We use a relational database to store human protein-encoding gene identifiers obtained primarily from NCBI Entrez and cross-referenced to the Human Genome Organisation

1
2 Nomenclature Committee (HGNC [25]) and NCBI RefSeq collections. For our purposes, we
3
4 group related identifiers into a functional 'locus' referring to a set of related gene or protein
5
6 product identifiers, which are considered to represent the same protein or set of transcripts.
7
8 Each 'locus' is assigned a unique, stable internal numeric identifier in the database so that all
9
10 identifiers associated with a given locus, even completely different historical Entrez GeneID,
11
12 HGNC and RefSeq identifiers, can be united and cross-referenced to older (or newer)
13
14 identifiers found in other studies. Additional information mined from Entrez GeneID, HGNC
15
16 and RefSeq collections are associated with each locus. These include current and obsolete
17
18 gene symbols and synonyms, official gene product names, chromosome and map locations,
19
20 UniProt [26] protein sequence identifiers, enzyme classification (EC) numbers, PubMed
21
22 literature identifiers and OMIM (<http://www.ncbi.nlm.nih.gov/omim>) identifiers for disease
23
24 associations. This forms the core of the database around which other types of data can be
25
26 assembled. As new data are added to the database, they can be cross-referenced to the
27
28 appropriate locus (for a single gene or gene product) or multiple loci (for relationships such
29
30 as protein-protein interactions).

30 **5.2 Processes and pathways**

31
32 A basic problem facing the researcher is to understand the contents of the screening library,
33
34 since individual gene product names and descriptions are often too terse or abstruse.
35
36 Systematised collections of general gene product descriptions exist in the form of ontologies,
37
38 the best known being the Gene Ontology project (GO [27]). GO associates curated terms
39
40 with genes according to three ontologies: molecular function, biological process, and cellular
41
42 component. The terms form three different networks (actually directed graphs), which are
43
44 stratified from the general to the specific, but allow multiple paths rather than enforcing a
45
46 strict hierarchy. In our workflow, hit genes are automatically mapped to GO annotations using
47
48 RNAither [21], for all three ontologies. Geneset enrichment analysis is then used to identify
49
50 categories and pathways containing more hits than would randomly be expected, using
51
52 topGO [28], to find molecular functions, biological processes and cellular compartments that
53
54 may be particularly important for viral replication.
55
56
57
58
59
60

1
2
3
4 Another ontology collection that is specialised for human, mouse, rat and the fruit fly is the
5 PANTHER Classification System [29], which is intended for use in high-throughput analysis
6 and is simplified accordingly. PANTHER biological processes cover almost half (about 11300
7 genes) of the human protein coding loci, although more coverage is obtainable by looking at
8 molecular function without placement in any particular process. The designers of PANTHER
9 have defined a set of about 30 top-level biological processes dealing with very general
10 (overlapping) cellular activities such as 'amino acid metabolism' or 'cell adhesion', and we
11 incorporate these into our core database to give a simplified overview, both of the genes in
12 the screening libraries and of the hits.

13
14
15
16
17
18
19
20
21
22 A second problem, having performed a screen and identified known pathways of interest, is
23 to visualise the hits in these pathways. High-quality pathway information is obtained from the
24 Kyoto Encyclopedia of Genes and Genomes (KEGG, [27]) in the form of navigable schematic
25 diagrams of metabolic and regulatory pathways, based on extensive literature mining across
26 multiple organisms. The maps are interactive and KEGG provides a simple API (Application
27 Programming Interface) for several common programming languages allowing selective
28 manipulation of the diagrams from locally written client applications communicating with the
29 KEGG server. Note however, that the KEGG pathway maps cover considerably less of the
30 human genome than PANTHER processes, accounting for slightly less than 4800 unique
31 genes. Clearly, no single process or pathway data source is sufficient to address every need,
32 and several need to be combined in an analysis.

33 34 35 36 37 38 39 40 41 42 **5.3 Interaction networks**

43
44
45 For many genes, the pathway data are insufficient to identify any relationship between the
46 hits from a screen. We then turn to protein-protein interaction networks and try to embed hits
47 and search for clusters.

48
49
50
51
52 A number of protein-protein interaction databases are publicly available, most of them
53
54
55
56
57
58
59
60

1
2 containing interaction data for multiple organisms. For a review of these databases focusing
3 on human-specific interactions, see [30]. These datasets vary according to the quality of the
4 data source and curation that they offer. Interactions may be predicted computationally or
5 obtained experimentally. Experimental observations may derive from high-throughput
6 analyses such as yeast two-hybrid, or from co-immunoprecipitation assays, with varying
7 degrees of confidence in the result. Similarly, the level of curation ranges from automatic
8 literature mining, through manual literature mining by biologists, to direct submission of
9 results by the investigator. One of the most comprehensive collections of human-only,
10 experimental interaction data is the Human Protein Reference Database (HPRD, [31],
11 <http://www.hprd.org/>), which is manually curated and includes details of the type of
12 experiment, the protein domains involved and post-translational modifications.

23
24 In general, the reliability of an interaction increases as more corroboratory evidence is found.
25 The STRING [32] database provides a merged multi-organism collection assembled from the
26 public interaction databases, together with other predictive information such as pathways and
27 expression profiles that are common across organisms. Each interaction is assigned an edge
28 weighting to indicate the degree of confidence in that interaction. We currently use the
29 STRING interactive web interface (<http://string.embl.de>) to visualise small networks as
30 graphs of nodes (proteins) and edges (interactions). Larger networks, such as the HPRD
31 dataset, are visualised using Cytoscape [33], which is a cross-platform Java program
32 (<http://www.cytoscape.org/>). The graph layout can be manipulated directly and the software
33 offers many different automatic layout schemes.

43
44 There are broadly two strategies to identifying interesting genes in these networks for further
45 study: First, given the known interactions of the pathogen with the host proteins, candidate
46 hits that lie within one or a few steps away from these "front-line" host genes on the known
47 host protein-protein interaction network are of interest, as they deepen our understanding of
48 known pathogen/host dependencies into the rest of the network. One can also look for
49
50
51
52
53
54
55
56
57
58
59
60

1
2 interaction neighbours of other published modulators, such as those found in other screens,
3
4 to extend the boundaries of these clusters. Second, one can search for novel, statistically
5
6 significant clusters of hit genes co-occurring in the known interaction network.
7

8
9 Much published information already exists for well studied organisms or pathogen/host
10
11 interactions such as HIV/human. Known information on HIV/host gene interactions is
12
13 available from the NIAID HIV interaction dataset [34]. This is also incorporated into our
14
15 database, allowing us to see which HIV proteins are known to be associated with any of our
16
17 screening hits, together with the nature of the interaction and the evidence for it. Similarly, the
18
19 collections of host factors described in previous published HIV screens [4-6] have been
20
21 mined from the papers and added to the database, allowing direct comparison of the degree
22
23 of overlap and gene composition of the various studies with each other and with our screens.
24

25 **5.4 Implementation**

26
27 All bioinformatics processing is performed under Linux. Regular updates of material from
28
29 NCBI and other data sources are automatically transferred and post-processed locally into
30
31 suitable form for subsequent stages. The relational database uses PostgreSQL. Applications
32
33 are written in Python, Perl or using UNIX scripting tools.
34

35 **5.5 Concluding remarks**

36
37 Known or suspected interaction networks around single identified genes can be mined from
38
39 bioinformatics databases to provide a connected sub-network, into which multiple hits from
40
41 the screen can be embedded and correlated with phenotypes of interest. A central
42
43 component of the bioinformatics strategy therefore is a database system to store and
44
45 process all this data effectively, since the amount and variety of types of data that need to be
46
47 managed, cross-referenced and queried is potentially huge and changing. Finally, the system
48
49 is also used to help selecting interesting and functionally related candidates from the primary
50
51 screen for validation screening, and for subsequent detailed experimental analysis. In the
52
53 case of a virus-host interaction screen as discussed in this paper, interesting hits need to be
54
55
56
57
58
59
60

1
2 mapped not only into host biological processes, but also, if possible, to sub-cellular
3
4 compartments and to associated stages of the virus life-cycle.
5
6
7

8 **6 Conclusion**

9

10 We have described a modular and flexible microscopy-based RNAi screening platform for
11 investigation of host factors involved in virus-host interaction. This uses a two-stage
12 procedure (primary and subsequent validation screen) comprising four main steps:
13
14 experimental assay, image analysis, statistical analysis and bioinformatics, each of which has
15
16 been presented in detail. The platform was demonstrated in stably CD4 expressing HeLa P4
17
18 cells using a modified infectious HIV-1 strain carrying a GFP reporter (HIV-1-AGFP). The
19
20 procedure was shown to be suitable for robust and sensitive detection of host cell factors
21
22 involved in HIV-1 replication using different cell culture formats.
23
24
25

26
27 Design and testing of standardised experimental setups for production of sufficient amounts
28
29 of virus were found to be critical to obtaining reliable and comparable datasets. Dedicated
30
31 image processing procedures were developed to process the very large amounts of high-
32
33 throughput image data (tens of terabytes over the lifetime of a full genome screen) in
34
35 reasonable time. Problems associated with the need for different data normalisation
36
37 approaches in primary and validation screens were addressed in the statistical analysis step,
38
39 which also deals with multiple potential sources of error in the readout. The bioinformatics
40
41 step integrates experimental results with data mined from public databases, allowing
42
43 screening hits to be functionally classified and embedded into known pathways and protein-
44
45 protein interaction networks.
46

47 Future extensions will include automated classification of images based on cell
48
49 morphologies, so that knockdown phenotypes can be classified in more detail and better
50
51 correlated with biological processes. Comparative analyses using other viruses on the same
52
53 platform will elucidate commonly used cellular host factors exploited by different viruses,
54
55
56
57
58
59
60

1
2 which may serve as novel drug targets for 'broad spectrum' antivirals. Finally, we would like
3
4 to encourage efforts at standardisation of RNAi screening procedures and offer our
5
6 experience with this platform as a robust basis on which to build new systems.
7
8
9

10 **Acknowledgements**

11
12 We thank Christiane Jost and Dirk Grimm for critical reading of the manuscript and Marc
13
14 Hemberger for IT support. This study was supported by the BMBF-funded project ViroQuant
15
16 (0313923). HGK and LK are members of the excellence cluster CellNetworks (EXC81). MJL
17
18 is supported by the Sonderforschungsbereich 638 (Dynamics of macromolecular complexes
19
20 in biosynthetic transport). The ViroQuant-CellNetworks RNAi Screening core facility would
21
22 like to acknowledge funding within the Forsys-ViroQuant consortium (0313923) as well as by
23
24 the Federal Ministry of Education and Research (BMBF). This work was supported by the
25
26 cluster of excellence CellNetworks at the University of Heidelberg (EXC81).
27

28 The authors have declared no conflict of interest.
29
30
31
32

33 **7 References**

- 34
35
36
37 [1] Carter, C. A., Ehrlich, L. S., Cell biology of HIV-1 infection of macrophages. *Annu Rev*
38
39 *Microbiol* 2008, 62, 425-443.
40
41 [2] Malim, M. H., Emerman, M., HIV-1 accessory proteins--ensuring viral survival in a hostile
42
43 environment. *Cell Host Microbe* 2008, 3, 388-398.
44
45 [3] Martin, N., Sattentau, Q., Cell-to-cell HIV-1 spread and its implications for immune
46
47 evasion. *Curr Opin HIV AIDS* 2009, 4, 143-149.
48
49 [4] Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., *et al.*, Identification of host proteins
50
51 required for HIV infection through a functional genomic screen. *Science* 2008, 319, 921-926.
52
53 [5] Konig, R., Zhou, Y., Elleder, D., Diamond, T. L., *et al.*, Global analysis of host-pathogen
54
55
56
57
58
59
60

- 1
2 interactions that regulate early-stage HIV-1 replication. *Cell* 2008, 135, 49-60.
- 3
4 [6] Zhou, H., Xu, M., Huang, Q., Gates, A. T., *et al.*, Genome-scale RNAi screen for host
5 factors required for HIV replication. *Cell Host Microbe* 2008, 4, 495-504.
- 6
7 [7] Bushman, F. D., Malani, N., Fernandes, J., D'Orso, I., *et al.*, Host cell factors in HIV
8 replication: meta-analysis of genome-wide studies. *PLoS Pathog* 2009, 5, e1000437.
- 9
10 [8] Goff, S. P., Knockdown screens to knockout HIV-1. *Cell* 2008, 135, 417-420.
- 11
12 [9] Prudencio, M., Lehmann, M. J., Illuminating the host - how RNAi screens shed light on
13 host-pathogen interactions. *Biotechnol J* 2009, 4, 826-837.
- 14
15 [10] Erfle, H., Neumann, B., Liebel, U., Rogers, P., *et al.*, Reverse transfection on cell arrays
16 for high content screening microscopy. *Nat Protoc* 2007, 2, 392-399.
- 17
18 [11] Erfle, H., Neumann, B., Rogers, P., Bulkescher, J., *et al.*, Work flow for multiplexing
19 siRNA assays by solid-phase reverse transfection in multiwell plates. *J Biomol Screen* 2008,
20 13, 575-580.
- 21
22 [12] Novina, C. D., Murray, M. F., Dykxhoorn, D. M., Beresford, P. J., *et al.*, siRNA-directed
23 inhibition of HIV-1 infection. *Nat Med* 2002, 8, 681-686.
- 24
25 [13] Welker, R., Harris, M., Cardel, B., Krausslich, H. G., Virion incorporation of human
26 immunodeficiency virus type 1 Nef is mediated by a bipartite membrane-targeting signal:
27 analysis of its role in enhancement of viral infectivity. *J Virol* 1998, 72, 8833-8840.
- 28
29 [14] Beucher, S., The watershed transformation applied to image segmentation *Scanning*
30 *Microscopy International* 1992, 299-314.
- 31
32 [15] Otsu, N., A threshold selection method from grey level histograms *IEEE Transactions on*
33 *Systems, Man, and Cybernetics* 1979, 9, 62-66.
- 34
35 [16] Lindblad, J., Bengtsson, E., A comparison of methods for estimation of intensity
36 nonuniformities in 2D and 3D microscope images of fluorescence stained cells. *Proceedings*
37 *of the 12th Scandinavian Conference on Image Analysis (SCIA)* 2001, 264-271.
- 38
39 [17] Cleveland, W. S., Robust locally weighted regression and smoothing scatterplots.
40 *American Statistical Association* 1979, 829-836.
- 41
42 [18] Brideau, C., Gunter, B., Pikounis, B., Liaw, A., Improved statistical methods for hit
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2 selection in high-throughput screening. *J Biomol Screen* 2003, 8, 634-647.
- 3
4 [19] Boutros, M., Bras, L. P., Huber, W., Analysis of cell-based RNAi screens. *Genome Biol*
5 2006, 7, R66.
- 6
7 [20] Malo, N., Hanley, J. A., Cerquozzi, S., Pelletier, J., Nadon, R., Statistical practice in high-
8 throughput screening data analysis. *Nat Biotechnol* 2006, 24, 167-175.
- 9
10 [21] Rieber, N., Knapp, B., Eils, R., Kaderali, L., RNAiR, an automated pipeline for the
11 statistical analysis of high-throughput RNAi screens. *Bioinformatics* 2009, 25, 678-679.
- 12
13 [22] Maglott, D., Ostell, J., Pruitt, K. D., Tatusova, T., Entrez Gene: gene-centered information
14 at NCBI. *Nucleic Acids Res* 2005, 33, D54-58.
- 15
16 [23] Pruitt, K. D., Tatusova, T., Maglott, D. R., NCBI reference sequences (RefSeq): a curated
17 non-redundant sequence database of genomes, transcripts and proteins. *Nucleic Acids Res*
18 2007, 35, D61-65.
- 19
20 [24] Hubbard, T. J., Aken, B. L., Ayling, S., Ballester, B., *et al.*, Ensembl 2009. *Nucleic Acids*
21 *Res* 2009, 37, D690-697.
- 22
23 [25] Eyre, T. A., Ducluzeau, F., Sneddon, T. P., Povey, S., *et al.*, The HUGO Gene
24 Nomenclature Database, 2006 updates. *Nucleic Acids Res* 2006, 34, D319-321.
- 25
26 [26] The universal protein resource (UniProt). *Nucleic Acids Res* 2008, 36, D190-195.
- 27
28 [27] Kanehisa, M., Goto, S., KEGG: kyoto encyclopedia of genes and genomes. *Nucleic*
29 *Acids Res* 2000, 28, 27-30.
- 30
31 [28] Alexa, A., Rahnenfuhrer, J., Lengauer, T., Improved scoring of functional groups from
32 gene expression data by decorrelating GO graph structure. *Bioinformatics* 2006, 22, 1600-
33 1607.
- 34
35 [29] Thomas, P. D., Campbell, M. J., Kejariwal, A., Mi, H., *et al.*, PANTHER: a library of
36 protein families and subfamilies indexed by function. *Genome Res* 2003, 13, 2129-2141.
- 37
38 [30] Mathivanan, S., Periaswamy, B., Gandhi, T. K., Kandasamy, K., *et al.*, An evaluation of
39 human protein-protein interaction data in the public domain. *BMC Bioinformatics* 2006, 7
40 *Suppl 5*, S19.
- 41
42 [31] Mishra, G. R., Suresh, M., Kumaran, K., Kannabiran, N., *et al.*, Human protein reference
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2 database--2006 update. *Nucleic Acids Res* 2006, *34*, D411-414.

3
4 [32] Jensen, L. J., Kuhn, M., Stark, M., Chaffron, S., *et al.*, STRING 8--a global view on
5 proteins and their functional interactions in 630 organisms. *Nucleic Acids Res* 2009, *37*,
6 D412-416.
7

8
9 [33] Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., *et al.*, Cytoscape: a software
10 environment for integrated models of biomolecular interaction networks. *Genome Res* 2003,
11 *13*, 2498-2504.
12

13
14 [34] Ptak, R. G., Fu, W., Sanders-Beer, B. E., Dickerson, J. E., *et al.*, Cataloguing the HIV
15 type 1 human protein interaction network. *AIDS Res Hum Retroviruses* 2008, *24*, 1497-1502.
16
17
18

21 Figure legends

25 Figure 1

27 Overview of the siRNA screening platform.

28
29 (A) Automated workflow consisting of the four main stage: infection assay, image analysis,
30 statistics and bioinformatics (boxes at left, running vertically downwards). Key sub-activities
31 of each stage are indicated (boxes to right). (B) Genome of the GFP-encoding infectious
32 HIV-1 particles. A portion of the viral *nef* gene (red) is replaced by GFP (green) [13]. (C)
33 Antibody staining against the viral capsid protein reveals GFP expression as a suitable
34 readout for infection in HeLa P4 cells. From left to right: (i) Hoechst 33258 stain to identify
35 individual cell nuclei. (ii) GFP expression after infection with GFP-encoding HIV-1 particles.
36 (iii) Antibody stain against the viral capsid protein p24. (iv) Overlay of GFP-expression and
37 anti-capsid stains with almost complete colocalisation indicating that almost all GFP-
38 expressing cells contain the viral capsid protein p24.
39
40
41
42
43
44
45
46
47

48 Figure 2

51 Enhancing or inhibiting effects of individual gene knockdowns on HIV-1-infection

imaged by fluorescence microscopy.

HeLa P4 cells were transfected with siRNAs and infected with AGFP-HIV-1 particles after 36 hr. After incubation for a further 36 hr, the cells were fixed and GFP and Hoechst images acquired by high-throughput fluorescence microscopy. **(A)** Correlation between z-scores of two replicates of an RNAi screen investigating host cell functions in HIV-1 pathogenesis with individual siRNA mediated gene knockdowns (grey), non-silencing control siRNAs (red) and CD4 positive controls (green). The Pearson correlation coefficient is 0.82. **(B)** Z-score distributions of the non-silencing control siRNA and the positive control CD4. The separation of the two distributions confirms CD4 as a significant down-regulator in our assay. **(C)** Hoechst stain, GFP-expression and the overlay for the non-silencing control siRNA and for representatives of down- and upregulating gene function in HIV-1 replication.

Figure 3**Image segmentation and infection cut-off**


(A) Epifluorescence microscopy image of AGFP-HIV-1 infected GFP-expressing cells with cell nuclei (blue) and GFP-expressing cells (green). **(B)** Segmentation of cell nuclei (blue spots). **(C)** Segmentation of cells showing individual infected cell bodies (green) **(D)** Histogram of mean grey values with fitted curves used to define infection cut-off criterion.

Deleted: ¶


¶
¶
¶
¶

Formatted: Justified

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



246x282mm (72 x 72 DPI)



653x587mm (72 x 72 DPI)

WILEY

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60